Based on an NGS strategy, Almodovar et al. analyzed serial plasma samples of 11 LD-SCLC and 16 ED-SCLC patients using a custom panel of the most frequently mutated genes in SCLC tumors, including TP53 and RB1 [69]. This evidence concerns the gene TP53 and small cell lung carcinoma.